Your browser doesn't support javascript.
loading
Treatment discontinuation with peg-interferon: what to consider.
Boccaccio, Vincenzo; Russo, Maria Luisa; Carbone, Marco; Bruno, Savino.
Afiliação
  • Boccaccio V; a 1 Internal Medicine and Hepatology Unit, Humanitas Research Hospital , Rozzano, Italy.
  • Russo ML; a 1 Internal Medicine and Hepatology Unit, Humanitas Research Hospital , Rozzano, Italy.
  • Carbone M; a 1 Internal Medicine and Hepatology Unit, Humanitas Research Hospital , Rozzano, Italy.
  • Bruno S; a 1 Internal Medicine and Hepatology Unit, Humanitas Research Hospital , Rozzano, Italy.
Expert Rev Clin Pharmacol ; 8(6): 761-8, 2015.
Article em En | MEDLINE | ID: mdl-26437265
Eradication of chronic hepatitis C virus infection improves the outcome of both liver and extrahepatic-related diseases and interferon-based regimens represented, for years, the standard of care to achieve this goal. Several baseline and on-treatment predictors of response, associated with a lower chance to achieve sustained virological response after interferon-based treatment, were developed. In the past few years, the advent of direct acting antivirals has dramatically modified the landscape of antiviral therapy, leading to an evolution from interferon-based to interferon-free therapies. This review will focus on the usefulness of futility stopping rules that allow the discontinuation of therapy in patients with a reduced chance to obtain sustained virological response if treated with interferon-containing regimens.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Interferons / Hepatite C Crônica Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Interferons / Hepatite C Crônica Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article